<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "amiodarone inj VIAL">
<dose><value>300</value>
<value>150</value>
<value>360</value>
<value>540</value>
<value>0.5</value>
<value>5000</value>
<value>5</value>
<value>6</value>
<value>7</value>
<value>7.5</value>
<value>8</value>
<value>9</value>
<value>10</value>
<value>11</value>
<value>12</value>
<value>13</value>
<value>14</value>
<value>15</value>
<value>2500</value>
<value>12.5</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>amiodarone inj VIAL</value>
</drugname><strength><value>50 mg/mL</value>
</strength><frequency><value>ONCE</value>
<value>CONTINUOUS</value>
</frequency><instruction><value>Administer by direct injection.</value>
<value>Supplemental rapid IV dose, if pulseless V-Tach or V-Fib continues or recurs.</value>
<value>Step 1: Administer dose over 10 minutes.</value>
<value>Step 2: Administer over 6 hours (1 mg/minute)</value>
<value>Step 3: Administer over the next 18 hours (0.5 mg/minute). </value>
<value>Administer by continuous infusion.</value>
<value>Rapid IV dose. Up to a maximum dose of 300 mg and may repeat dose up to a daily maximum dose of 15 mg/kg/day. (Maximum daily dose in adolescents = 2.2 g.</value>
<value>Administer by continuous infusion, titrate to desired response or a maximum dose of 15 mcg/kg/minute</value>
<value>LOADING DOSE: Administer over 20 to 60 minutes. If hemodynamically tolerated, may repeat dose for a total of 5000 mcg/kg over 60 to 120 minutes.</value>
<value>Administer by continuous infusion, titrate to desired response.</value>
</instruction><volume><value>3 mL</value>
<value>6 mL</value>
<value>9 mL</value>
</volume><units><value>mg</value>
<value>mg/min</value>
<value>mcg/kg</value>
<value>mcg/kg/minute</value>
</units><additionalnotes><value>ACLS - Cardiac Arrest due to pulseless V-Tav or V-Fib. Not recommended for use in patients receiving Sovaldi or Harvoni in combination with another direct acting antiviral. Risk of serious symptomatic bradycardia. Health Canada: April 2, 2015. </value>
<value>Step 1: Ventricular and Atrial Tachycardia protocol. Not recommended for use in patients receiving Sovaldi or Harvoni in combination with another direct acting antiviral. Risk of serious symptomatic bradycardia. Health Canada: April 2, 2015. </value>
<value>Step 2: Ventricular and Atrial Tachycardia protocol. Not recommended for use in patients receiving Sovaldi or Harvoni in combination with another direct acting antiviral. Risk of serious symptomatic bradycardia. Health Canada: April 2, 2015. </value>
<value>Step 3: Ventricular and Atrial Tachycardia protocol. Not recommended for use in patients receiving Sovaldi or Harvoni in combination with another direct acting antiviral. Risk of serious symptomatic bradycardia. Health Canada: April 2, 2015. </value>
<value>Not recommended for use in patients receiving Sovaldi or Harvoni in combination with another direct acting antiviral. Risk of serious symptomatic bradycardia. Health Canada: April 2, 2015. </value>
<value>PALS: Treatment of Pulseless V-Tach or V-Fib. Not recommended for use in patients receiving Sovaldi or Harvoni in combination with another direct acting antiviral. Risk of serious symptomatic bradycardia. Health Canada: April 2, 2015. </value>
<value></value>
<value>Neonate: Refractory Perfusing Tachyarrhythmias</value>
<value>ACLS - Cardiac Arrest due to pulseless V-Tav or V-Fib.</value>
<value>Step 1: Ventricular and Atrial Tachycardia protocol</value>
<value>Step 2: Ventricular and Atrial Tachycardia protocol</value>
<value>Step 3: Ventricular and Atrial Tachycardia protocol</value>
<value>PALS: Treatment of Pulseless V-Tach or V-Fib.</value>
<value>Infant/Child dosing</value>
</additionalnotes><population><value>ADULT</value>
<value></value>
<value>INFANT/CHILDREN</value>
<value>NEONATE</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value></value>
</backgroundinformation><prninformation><value></value>
<value>YES</value>
</prninformation><ahsformularystatus><value>Formulary.</value>
<value>Discontinued.</value>
</ahsformularystatus><ahfsname><value>Cardiac Drugs, Antiarrhythmic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>